Dual targeting of EGFR and β1-integrin by inhibitory antibodies cetuximab and AIIB2, respectively [76], or EGFR and FAK [83], further enhanced the radiation response of HNSCC when compared with single treatment. The gene discussed is PTK2; the disease is head and neck squamous cell carcinoma.